383 related articles for article (PubMed ID: 28143405)
1. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
[TBL] [Abstract][Full Text] [Related]
2. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA
Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424
[TBL] [Abstract][Full Text] [Related]
3. Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein mice.
Ekmark-Lewén S; Lindström V; Gumucio A; Ihse E; Behere A; Kahle PJ; Nordström E; Eriksson M; Erlandsson A; Bergström J; Ingelsson M
Brain Behav; 2018 Mar; 8(3):e00915. PubMed ID: 29541535
[TBL] [Abstract][Full Text] [Related]
4. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
Schell H; Hasegawa T; Neumann M; Kahle PJ
Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
[TBL] [Abstract][Full Text] [Related]
5. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
6. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
Zhou W; Milder JB; Freed CR
J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
[TBL] [Abstract][Full Text] [Related]
7. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.
Richter F; Subramaniam SR; Magen I; Lee P; Hayes J; Attar A; Zhu C; Franich NR; Bove N; De La Rosa K; Kwong J; Klärner FG; Schrader T; Chesselet MF; Bitan G
Neurotherapeutics; 2017 Oct; 14(4):1107-1119. PubMed ID: 28585223
[TBL] [Abstract][Full Text] [Related]
8. Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease.
Magen I; Torres ER; Dinh D; Chung A; Masliah E; Chesselet MF
J Parkinsons Dis; 2015; 5(3):669-680. PubMed ID: 25588356
[TBL] [Abstract][Full Text] [Related]
9. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
Fleming SM; Mulligan CK; Richter F; Mortazavi F; Lemesre V; Frias C; Zhu C; Stewart A; Gozes I; Morimoto B; Chesselet MF
Mol Cell Neurosci; 2011 Mar; 46(3):597-606. PubMed ID: 21193046
[TBL] [Abstract][Full Text] [Related]
10. Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy.
Schaser AJ; Stackhouse TL; Weston LJ; Kerstein PC; Osterberg VR; López CS; Dickson DW; Luk KC; Meshul CK; Woltjer RL; Unni VK
Acta Neuropathol Commun; 2020 Aug; 8(1):150. PubMed ID: 32859276
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson's disease.
Zhang LF; Yu XL; Ji M; Liu SY; Wu XL; Wang YJ; Liu RT
Food Funct; 2018 Dec; 9(12):6414-6426. PubMed ID: 30462117
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
[TBL] [Abstract][Full Text] [Related]
13. Locomotor differences in mice expressing wild-type human α-synuclein.
Giraldo G; Brooks M; Giasson BI; Janus C
Neurobiol Aging; 2018 May; 65():140-148. PubMed ID: 29477894
[TBL] [Abstract][Full Text] [Related]
14. Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model.
Wang W; Song N; Jia F; Tang T; Bao W; Zuo C; Xie J; Jiang H
Neurochem Int; 2018 Mar; 114():71-79. PubMed ID: 29355568
[TBL] [Abstract][Full Text] [Related]
15. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
16. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Fleming SM; Salcedo J; Hutson CB; Rockenstein E; Masliah E; Levine MS; Chesselet MF
Neuroscience; 2006 Nov; 142(4):1245-53. PubMed ID: 16934409
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.
Rockenstein E; Nuber S; Overk CR; Ubhi K; Mante M; Patrick C; Adame A; Trejo-Morales M; Gerez J; Picotti P; Jensen PH; Campioni S; Riek R; Winkler J; Gage FH; Winner B; Masliah E
Brain; 2014 May; 137(Pt 5):1496-513. PubMed ID: 24662516
[TBL] [Abstract][Full Text] [Related]
18. Diffusion Kurtosis Imaging Detects Microstructural Alterations in Brain of α-Synuclein Overexpressing Transgenic Mouse Model of Parkinson's Disease: A Pilot Study.
Khairnar A; Latta P; Drazanova E; Ruda-Kucerova J; Szabó N; Arab A; Hutter-Paier B; Havas D; Windisch M; Sulcova A; Starcuk Z; Rektorova I
Neurotox Res; 2015 Nov; 28(4):281-9. PubMed ID: 26153486
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice.
Freichel C; Neumann M; Ballard T; Müller V; Woolley M; Ozmen L; Borroni E; Kretzschmar HA; Haass C; Spooren W; Kahle PJ
Neurobiol Aging; 2007 Sep; 28(9):1421-35. PubMed ID: 16872721
[TBL] [Abstract][Full Text] [Related]
20. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.
Paumier KL; Sukoff Rizzo SJ; Berger Z; Chen Y; Gonzales C; Kaftan E; Li L; Lotarski S; Monaghan M; Shen W; Stolyar P; Vasilyev D; Zaleska M; D Hirst W; Dunlop J
PLoS One; 2013; 8(8):e70274. PubMed ID: 23936403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
